**Supplement 3: Summary of chloroquine phosphate and hydroxychloroquine sulfate dose regimen from registered clinical trials in the COVID-19 treatment (21 Feb 2020)**

|  |  |  |
| --- | --- | --- |
| Registration number | Title | Dose regimen |
| ChiCTR2000030054 | An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of mild and common novel coronavirus pneumonia (COVID-19) | Experimental group 1 (n=40): 1000 mg chloroquine phosphate QD for first 2 days, 500 mg chloroquine phosphate QD for 12 days; Experimental group 2 (n=40): 200 mg hydroxychloroquine sulfate BID for14 days; Control group (n=20): conventional treatment |
| ChiCTR2000030031 | A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19) | Experimental group (n=80): 500 mg phosphoric chloroquine BID, combined with conventional treatment ;Control group (n=40): placebo combined with conventional treatment  |
| ChiCTR2000029837 | A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard  therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19) | Experiment group (n=80): 500 mg chloroquine phosphate BID, combined with conventional treatment;Control group (n=40) : placebo combined with conventional treatment |
| ChiCTR2000029826 | A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard  therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19) | chloroquine phosphate (n=30): 500 mg chloroquine phosphate BIDControl group(n=15): placebo |
| ChiCTR2000029542 | A prospective cohort study for the efficacy and safety of chloroquine in hospitalized patients with novel coronavirus pneumonia (COVID-19) | Experiment group (n=10): oral 500 mg BID for a 10-day chloroquine phosphate combined with conventional management;Control group (n=10): conventional treatment |
| ChiCTR2000029975 | Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19) | In addition to the conventional treatment, add 150 mg chloroquine phosphate dissolved in 5 mL of normal saline, BID, inhaled by atomization for one week (n=10) |
| ChiCTR2000029992 | An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of severe novel coronavirus pneumonia (COVID-19) | Chloroquine phosphate group (N=40):1000 mg for the first 2 days, 500 mg QD for 12 days from the third day;Hydroxychloroquine sulfate group (N=40) 200 mg BID for 14 days; Control group (N=20): conventional treatment |
| ChiCTR2000029868 | Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a multicenter, randomized controlled trial | Treatment group (n=100): conventional treatment combined with oral hydroxychloroquine sulfate tablets 400 mg TID (day1 to day3) and hydroxychloroquine sulfate tablets 400 mg BID (day 4 to day 14);Control group (n=100): conventional treatment |
| ChiCTR2000029740 | Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients | Hydroxychloroquine group (n=120)：oral  hydroxychloroquine 200 mg BIDControl group (n=120)：conventional therapy |
| ChiCTR2000029559 | Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19) | Experimental group 1 (n=100): hydroxychloroquine 100 mg oral BID Experimental group 2 (n=100): hydroxychloroquine 200 mg oral BIDControl group (n=100): placebo |